Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Genetic Testing Raises Complex Legal, Ethical, Social Issues

July 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

BALTIMORE-“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

BALTIMORE—“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

“Genetic testing produces data different from other kinds of medical information,” Ms. Rothenberg said. She referred to the distinctions as the “six P’s” (see Table ). Genetic information, she said, is “personal, powerful, potentially predictive, pedigree sensitive, permanent, and prejudicial.”

The Six P’s of Genetic Information

Genetic Information Is:

Personal (as unique as an individual’s DNA)

Powerful (or may appear to be)

Potentially predictive (of future health problems)

Pedigree sensitive (it is not just about individuals, but about their families, who may not want the information)

Permanent (currently, or at least not easily changed by gene therapy)

Prejudicial (historically used to discriminate against populations)

Legal issues that may crop up when dealing with genetic testing include informed consent, discrimination, privacy, liability, and family rights. She provided specific examples and advice on how to avoid potential legal problems.

 Informed consent has its benefits and risks, but its context is constantly changing, she said. For instance, the predictive value of a genetic test may not be known or may have varying usefulness in diagnosis. There is a risk of misinterpretation among patients or in the community, or there may be limited data on the effectiveness of preventive or interventional strategies.

 The effect on health behavior may not always be straightforward. Would a hypothetical test for lung cancer susceptibility, for example, empower or paralyze people? Would a negative test free people from the fear of lung cancer and so encourage them to smoke—leading to other smoking-related illnesses?

“There is great difficulty in quantifying social risk,” Ms. Rothenberg said. “Much depends on patients’ personal histories. The views of two people may differ depending on whether they see themselves as ‘healthy’ or a cancer patient.”

 Legal prohibitions on genetic discrimination in health insurance have been proposed and passed in some states, she said. Generally, these have stated that insurance companies may not require or request genetic tests, may not ask for results, may not base coverage or benefits on genetic testing, and may not consider genetic testing in determining rates.

While these laws were enacted to protect consumers, they share a number of problems. “Most focus on test results, but say nothing of family history or other sources of information,” she said (although a new Maryland law covers this point). “Half the people in the United States get their health insurance under ERISA, which is not included under state legal protection, so we need a federal solution. Now we’re trying to educate Congress so we can reap the benefit of the Human Genome Project.”

The federal Health Insurance Portability and Accountability Act (HIPAA, or the Kennedy-Kassebaum Act) states that genetic information cannot be considered a pre-existing condition, nor can it be used to determine insurance eligibility. But the bill says nothing about genetic privacy rights or about the practice of requesting genetic testing as a condition of medical coverage.

On the other hand, the Equal Employment Opportunity Commission has interpreted the Americans with Disability Act to say that a disability may be created on the basis of genetic information, citing predisposition to colon cancer as an example. However, this interpretation has not yet been tested in the courts.

“Thus we need a federal law saying that employers cannot discriminate on the basis of genetic information,” Ms. Rothenberg said. Congress might decide to deal with employment and health insurance issues together or by specific genetic legislation on each topic.

Family issues. “Perhaps the most complex questions arise not in Congress,” Ms. Rothenberg said, “but at the intersection of medical knowledge, ethical issues, and family dynamics.” The individual autonomy model that is a part of contemporary medical ethics “crumbles when testing genetics,” she said. “The family is the unit under discussion, not the individual.”

Both patients and their families may believe they have a right to know the outcome of genetic tests—and a right not to know, as well. Genetic information can throw a harsh light onto social and genetic relationships and intergenerational issues. Expectations of privacy may vary widely, and laws generally do not specifically immunize health care providers against lawsuits based on their giving or not giving genetic information.

“We value information in the health care system,” she said. “Doctors, genetic counselors, and nurses have to do good risk assessment with patients and then maintain good communication with their families when that is desired.”

Deciding on genetic testing for children depends on the disease and on the test. Children aren’t ordinarily tested for adult-onset diseases until they reach majority status. “Parental anxiety is not sufficient reason to test,” she said, although there may be a few cases in which medical benefits outweigh psychological harm.

“But there are professionals who believe it is medically appropriate to offer genetic testing if you are looking for a childhood disease, there is an effective intervention, and the test can be adequately interpreted,” she said.

Genetic information is already a part of family law and the court system. “When people fight each other in court, they want to win,” she said, and that means bringing any available evidence.

Besides the obvious area of paternity, Ms. Rothenberg said, genetic testing might be dragged into custody battles in divorce trials. “Could a mother with a mutation predisposing her to breast cancer, for example, be denied custody of her children because the father believes he will live longer?” she hypothesized. A court might rule it would be in “the best interest of the child” to live with the parent who did not have a genetic predisposition to disease.

Finally, Ms. Rothenberg asked, “how can law support health care providers in taking the right steps in the age of genetic information?” She gave this advice:

Disclose to patients the benefits, risks, and limitations of genetic testing. “Studies have show that if something goes wrong in the operating room, the patient is more likely to sue if prior communication was lacking,” she said.

Follow up and stay in contact with the patient after genetic testing. Establish and maintain a working doctor-patient relationship.

Maintain confidentiality.

Be aware of the risk to others of genetic information and talk to patients about those issues.

Anticipate potential legal, ethical, and social issues before testing.

Understand the dynamics of the patient’s family. Encourage family involvement but be aware of potential problems.

Avoid coercion by the patient’s family or by other health care providers to reveal test results.

Be aware of applicable state and federal laws.

Articles in this issue

Nasal Angiogenesis Inhibitor May Stop Kaposi’s Sarcoma
Surgeon’s Perspective on Neoadjuvant Chemo for Breast Cancer
STAR Breast Cancer Prevention Trial Begins Enrollment
Studies Suggest New Approaches in Hereditary Ovarian Cancer
Lycopene Beneficial in Prostate Cancer
Komen Launches REMEMBER
Advice and Support for Daughters of Breast Cancer Patients
Fetus May Be Harmed by Second-Hand Smoke
Genes Linked to Smoking Affinity, Smoking-Induced Lung Cancer
Ultraviolet Light Slated for Review as Carcinogen
NCI Funding Complementary/Alternative Medicine Trials
COX2 Inhibitors Promising in Prevention
Colon Cancer Cases Show Dilemmas of Genetic Testing
Vitamin Supplementation Appears to Protect Against p53 Mutations
Genetic Testing Raises Complex Legal, Ethical, Social Issues
Recent Videos
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
2 KOLs are featured in this series.
Related Content
Advertisement

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Related Content
Advertisement

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.